Glaxo’s Best ‘Headache’ Remedy May Be Buying Stakes in Ventures

The drugmaker's profit has been declining as its best-selling Advair faces more competition
Updated on

Two of GlaxoSmithKline’s most promising businesses—its joint ventures in HIV drugs and consumer health—harbor both a threat and an opportunity, with a price tag in the billions.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.